14 September 2026
Dr. Frederick D. Sancilio, Chairman and CEO, will present clinical and preclinical data for Conjugated Psilocin™ (L-130) at the 9th Neuropsychiatric Drug Development Summit, held September 15-17, 2026 in Boston, Massachusetts. His talk, “Reimagining Psychedelic Therapeutics for Daily Outpatient Use,” is scheduled for 11:00 a.m. ET on Wednesday, September 16 in the preclinical and translational track. The presentation covers Phase 1a first-in-human results, including oral bioavailability, dose consistency, and the absence of hallucinogenic effects at low doses.
28 August 2026
28 August 2026
20 August 2026
Lobe Sciences Ltd. announced the closing of its previously announced non-brokered private placement of 24,705,880 common shares at $0.085 per share, generating aggregate gross proceeds of approximately $2.1 million. The Company intends to use the proceeds for working capital and general corporate purposes, as well as to advance its S-100 drug candidate for sickle cell disease, with funding directed to Applied Lipid Technologies to support development toward human clinical trials.
12 August 2026
Lobe Sciences Ltd. announced a non-brokered private placement of 24,705,880 common shares at $0.085 per share for aggregate gross proceeds of approximately $2.1 million. The Company intends to use the net proceeds to strengthen cash reserves, support further clinical development of S-100 through Applied Lipid Technologies, and fund working capital and general corporate purposes, subject to required regulatory approvals.
05 August 2026
Lobe Sciences Ltd. announced the results of its Annual General and Special Meeting of Shareholders, where shareholders approved all matters presented, including the election of directors, the appointment of the Company’s auditor, and other items of corporate business outlined in the Management Information Circular. The Company thanked shareholders for their continued support as it advances its strategic and operational objectives.
07 July 2026
Lobe Sciences Ltd. announced that it has filed its Management Information Circular and related meeting materials in connection with its upcoming Annual General and Special Meeting of Shareholders. The materials are available on the Company’s website and through SEDAR+, providing shareholders with information regarding the matters to be considered at the meeting, including the election of directors and other corporate business.
09 June 2026
Lobe Sciences Ltd. announced that its directors and management have increased their equity ownership in the Company through the settlement of outstanding compensation obligations. The transaction resulted in the issuance of common shares in satisfaction of accrued fees and compensation, aligning leadership interests more closely with shareholders while preserving the Company’s cash resources for ongoing operations and development activities.
01 June 2026
Lobe Sciences Ltd. announced a proposed shares-for-debt transaction to settle approximately C$1.37 million in outstanding management and director fees through the issuance of 12,749,643 common shares at a deemed price of $0.11 per share. The Company stated that the proposed settlement is intended to preserve cash resources for ongoing operations and development activities, subject to regulatory approval, including acceptance by the Canadian Securities Exchange.
06 May 2026
Lobe Sciences Ltd. announced that Chief Executive Officer Dr. Frederick D. Sancilio will attend the D. Boral Capital Global Conference in New York on May 7, 2026, where he will be available to meet with institutional investors, pharmaceutical companies, and potential strategic partners. The Company also highlighted continued advancement of its L-130 and S-100 development programs through its subsidiary structure.
06 May 2026
Lobe Sciences Ltd. reported second quarter 2026 results and provided an operational update, highlighting continued advancement of its L-130 and S-100 programs. The Company reported cash of $1.07 million, short-term investments of $3.89 million, and noted that it completed a $950,000 non-brokered private placement subsequent to quarter-end to support ongoing development activities.
28 April 2026
ArcStone Financial Pulse has published a Company Feature Report on Lobe Sciences Ltd., outlining the Company’s development platform, subsidiary structure, financial position, intellectual property portfolio, and clinical-stage programs across Cynaptec Pharmaceuticals and Applied Lipid Technologies.
23 April 2026
Lobe Sciences Ltd. commented on the recent White House Executive Order supporting drug development for neurological and mental health disorders, stating that the policy shift may help advance scientific research in areas historically constrained by regulation. The Company also noted that its subsidiary, Cynaptec Pharmaceuticals, is continuing to advance L-130 for chronic cluster headache and substance use disorder.
21 April 2026
Lobe Sciences Ltd. announced that it has engaged Massive Intelligence Pty Ltd. to provide investor relations and corporate communications services under an initial three-month agreement commencing April 15, 2026. The engagement includes development of investor materials and corporate communications content for distribution through social media, email, and press releases.
20 April 2026
Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update
Lobe Sciences Ltd. announced the closing of its previously disclosed non-brokered private placement, raising approximately $950,000 in gross proceeds. The proceeds are intended to support working capital, general corporate purposes, and advancement of the Company’s S-100 drug candidate for sickle cell disease through Applied Lipid Technologies toward human clinical trials.
10 April 2026
Lobe Sciences Ltd. announced a non-brokered private placement of 14,615,384 common shares at a price of $0.065 per share for aggregate gross proceeds of approximately $950,000. The Company intends to use the net proceeds for working capital and general corporate expenses, subject to required regulatory approvals, including Exchange acceptance.
25 Mar 2026
Lobe Sciences Ltd. reported significant improvement in its financial position and capital structure, including lower liabilities, higher cash, improved working capital, and reduced warrants. The Company also outlined a more capital efficient subsidiary based operating model intended to support disciplined advancement of its development programs.
09 Mar 2026
Lobe Sciences Ltd. announces the appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer, effective March 2, 2026. Mr. Rahimani has been advising management and the Board since December 1, 2025 and brings significant experience in public-company financial reporting, governance, strategic transactions, financings, and compliance.
05 Mar 2026
Lobe Sciences Ltd. announces its presence in Miami during the Jefferies and Leerink Healthcare Conferences, where CEO Dr. Frederick D. Sancilio will meet with investors and industry stakeholders.
13 Jan 2026
Lobe Sciences appointed Nick Karakochuk to Board of Directors to advance governance and capital markets expertise.
6 Jan 2026
Lobe Sciences reported fiscal 2025 results and highlighted strategic transformation following leadership transition.
9 Oct 2025
Lobe Sciences announced improvements to balance sheet.
5 June 2025
Lobe Sciences appointed Yong Yao as Chief Financial Officer to support strategic growth.
14 Apr 2025
Lobe Sciences announced a non-brokered private placement of preferred shares in Cynaptec Pharmaceuticals for US$6M with option for US$20M. Cynaptec will own and develop Conjugated PsilocinTM.
4 Apr 2025
Lobe Sciences provided corporate update regarding recent transactions including issuance of convertible notes and common shares in settlement of accounts payable.
17 Mar 2025
Lobe Sciences announced appointment of Dr. Herman Williams as CEO of Altemia, Inc. Altemia is a medical food for sickle cell disease deficiencies, launching in 2025.
18 Nov 2024
U.S. Patent Office issued notice of allowance for second patent for Conjugated PsilocinTM. Patent covers psilocin mucate compositions and will provide additional coverage.
16 Oct 2024
Lobe Sciences appointed Enclave Capital and Peak Asset Management to raise funds for Conjugated Psilocin™ development through FDA NDA process.
2 Oct 2024
USPTO issued U.S. Patent 12,102,616 titled “Psilocin Mucate” covering compositions, methods of use and production for Conjugated Psilocin™. Valid until July 2043.